Study Reveals Impaired Glymphatic Function in Patients with ME/CFS

A study published in *Frontiers in Neuroscience* on June 19, 2026, has identified impaired glymphatic function in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). This research, which utilized diffusion tensor imaging along the perivascular space (DTI-ALPS), involved 58 participants, comprising 31 individuals with ME/CFS and 27 healthy controls. Findings indicated that the overall DTI-ALPS index for glymphatic function was significantly lower in ME/CFS patients, measuring 1.44±0.086 compared to 1.51±0.11 in healthy controls (p=0.014).

The right hemisphere in ME/CFS patients also showed a lower DTI-ALPS index (1.41±0.097) compared to healthy controls (1.49±0.12; p=0.009), while no significant differences were noted in the left hemisphere. Additionally, an association between the DTI-ALPS index and the severity of sleep disturbances (p=0.013, r=−0.47) and impaired concentration (p=0.026, r=−0.43) was observed, suggesting that reduced glymphatic function may contribute to cognitive dysfunction and sleep disturbances experienced by individuals with ME/CFS.

The glymphatic system is a crucial brain waste clearance mechanism, which operates primarily during sleep. Impaired glymphatic function may lead to the accumulation of metabolic waste, promoting neuroinflammation and neurological symptoms prevalent in ME/CFS. The study's authors suggest this underscores the potential need for addressing glymphatic dysfunction in therapeutic strategies for ME/CFS.

The study was conducted at the National Centre for Neuroimmunology and Emerging Diseases (NCNED) in Queensland, Australia, with approval from Griffith University’s Human Research Ethics Committee (Ref: 2022/666). The recruitment followed specific diagnostic criteria for ME/CFS and excluded individuals with a history of COVID-19 or other significant comorbid conditions.

Overall, this research highlights a novel avenue for understanding the biological underpinnings of ME/CFS and the relationship between glymphatic function and symptom severity, offering hope for future interventions aiming to improve patient outcomes.